In September 2025, TG Therapeutics presented updated six-year data from the ULTIMATE I & II Phase 3 trials of BRIUMVI® (ublituximab-xiiy) for relapsing multiple sclerosis at the ECTRIMS annual meeting ...
If you want to know who really controls TG Therapeutics, Inc. (NASDAQ:TGTX), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback